Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Askling

Showing results (131-140 of 345) with videos related to

Pageof 35
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 2, 2011
Coeliac disease characteristics, compliance to a gluten free diet and risk of lymphoma by subtypeOla Olén, Johan Askling, Jonas F Ludvigsson, et al.
Arthritis Research & Therapy|December 4, 2016
A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy - results from a Swedish cohort studyXia Jiang, Johan Askling, Saedis Saevarsdottir, et al.
Arthritis Care & Research|January 3, 2013
Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetrationJonas K Eriksson, Martin Neovius, Sofia Ernestam, et al.
Rheumatology (Oxford, England)|August 19, 2020
Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtypeKarin Hellgren, Daniela Di Giuseppe, Karin E Smedby, et al.
Plos One|November 26, 2014
Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjectsAne Krag Jakobsen, Lennart T H Jacobsson, Oliver Patschan, et al.
Annals of the Rheumatic Diseases|December 15, 2017
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologicsThomas Frisell, Eva Baecklund, Karin Bengtsson, et al.
Hepatology (Baltimore, Md.)|December 17, 2009
Decreased survival of subjects with elevated liver function tests during a 28-year follow-upCecilia Söderberg, Per Stål, Johan Askling, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 4, 2015
Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case-control studyÄngla Mantel, Marie Holmqvist, Fredrik Nyberg, et al.
The Journal of Rheumatology|April 2, 2021
Tuberculosis in Biologic-naïve Patients With Rheumatoid Arthritis: Risk Factors and Tuberculosis CharacteristicsJohanna Karlsson Sundbaum, Elizabeth V Arkema, Judith Bruchfeld, et al.
Rheumatology (Oxford, England)|March 23, 2015
Does disease activity at the start of biologic therapy influence health care costs in patients with RA?Kari Johansson, Jonas K Eriksson, Ronald van Vollenhoven, et al.
Pageof 35

Showing results (131-140 of 345) with videos related to

Sort By:
Pageof 35
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 2, 2011
Coeliac disease characteristics, compliance to a gluten free diet and risk of lymphoma by subtypeOla Olén, Johan Askling, Jonas F Ludvigsson, et al.
Arthritis Research & Therapy|December 4, 2016
A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy - results from a Swedish cohort studyXia Jiang, Johan Askling, Saedis Saevarsdottir, et al.
Arthritis Care & Research|January 3, 2013
Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetrationJonas K Eriksson, Martin Neovius, Sofia Ernestam, et al.
Rheumatology (Oxford, England)|August 19, 2020
Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtypeKarin Hellgren, Daniela Di Giuseppe, Karin E Smedby, et al.
Plos One|November 26, 2014
Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjectsAne Krag Jakobsen, Lennart T H Jacobsson, Oliver Patschan, et al.
Annals of the Rheumatic Diseases|December 15, 2017
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologicsThomas Frisell, Eva Baecklund, Karin Bengtsson, et al.
Hepatology (Baltimore, Md.)|December 17, 2009
Decreased survival of subjects with elevated liver function tests during a 28-year follow-upCecilia Söderberg, Per Stål, Johan Askling, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 4, 2015
Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case-control studyÄngla Mantel, Marie Holmqvist, Fredrik Nyberg, et al.
The Journal of Rheumatology|April 2, 2021
Tuberculosis in Biologic-naïve Patients With Rheumatoid Arthritis: Risk Factors and Tuberculosis CharacteristicsJohanna Karlsson Sundbaum, Elizabeth V Arkema, Judith Bruchfeld, et al.
Rheumatology (Oxford, England)|March 23, 2015
Does disease activity at the start of biologic therapy influence health care costs in patients with RA?Kari Johansson, Jonas K Eriksson, Ronald van Vollenhoven, et al.
Pageof 35